Table 1.
Caloric intake, body and liver weight, liver damage and intestinal permeability of C57BL/6J mice fed a SFC concomitantly treated with infliximab or vehicle.
| Control |
SFC |
Control |
SFC |
|
|---|---|---|---|---|
| + Vehicle | + Infliximab | |||
| Caloric intake (kcal/g/bw) | 0.45 ± 0.00 | 0.43 ± 0.01 | 0.43 ± 0.01 | 0.44 ± 0.01 |
| Body weight (g) | 28.1 ± 0.5 | 31.4 ± 0.5a,c | 28.5 ± 0.9 | 29.4 ± 0.6 |
| Absolute body weight gain (g) | 5.0 ± 0.7 | 8.7 ± 0.5a,c | 4.7 ± 0.6 | 6.5 ± 0.9 |
| Liver weight (g) | 1.4 ± 0.0 | 1.7 ± 0.1a,c | 1.4 ± 0.1 | 1.6 ± 0.1 |
| Liver:body weight ratio (%) | 4.9 ± 0.1 | 5.2 ± 0.1 | 5.0 ± 0.1 | 5.4 ± 0.2 |
| Steatosis (NAS) | 0.34 ± 0.1 | 1.83 ± 0.1a,c | 0.15 ± 0.1 | 1.38 ± 0.2a,c |
| Inflammation (NAS) | 0.00 ± 0.0 | 0.46 ± 0.1a,c,d | 0.00 ± 0.0 | 0.17 ± 0.1a,c |
| ALT (U/L) | 17.3 ± 2.2 | 27.2 ± 2.8 | 24.0 ± 5.3 | 28.3 ± 3.0 |
| MPO activity (% over control) | 100.0 ± 8.9 | 343.6 ± 97.1a,c | 111.7 ± 17.3 | 153.3 ± 24.9 |
| Endotoxin (OD 655 nm) | 0.18 ± 0.01 | 0.27 ± 0.01a,c | 0.17 ± 0.01 | 0.30 ± 0.02a,c |
| aSma mRNA expression | 100.0 ± 20.3 | 119.2 ± 26.1 | 98.8 ± 14.4 | 119.0 ± 28.3 |
| Col1a1 mRNA expression | 100.0 ± 14.7 | 151.9 ± 44.8 | 159.3 ± 25.3 | 165.4 ± 22.7 |
Data are shown as mean ± SEM, n = 6–8; ap < 0.05 compared to C-fed + Vehicle-treated mice, cp < 0.05 compared to C-fed + Infliximab-treated mice, dp < 0.05 compared to SFC-fed + Infliximab-treated mice. aSma, alpha smooth muscle actin; ALT, alanine aminotransferase; Col1a1, collagen type I alpha1; C, control diet; MPO, myeloperoxidase; NAS, NAFLD activity score; SFC, sucrose-, fat-, and cholesterol-rich diet.